Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement - Royalty Pharma (NASDAQ:RPRX), Ascendis Pharma (NASDAQ:ASND)

• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma

Related Keywords

California ,United States ,Heidelberg ,Baden Wüberg ,Germany ,Berlin ,Munich ,Bayern ,Copenhagen ,Køavn ,Denmark ,Ukraine ,Russia ,New Jersey ,Redwood City ,Jan Mikkelsen ,Johnson Tremfya ,Latham Watkins ,Johnson Imbruvica ,Melinda Baker ,Pablo Legorreta ,Tim Lee ,Novarti Promacta ,Kromann Reumert ,Roche Evrysdi ,Ascendis Pharma ,Patti Bank ,Us Food Drug Administration ,Exchange Commission ,Goodwin Procter ,Endocrine Rare Disease ,Royalty Pharma ,Chief Executive ,Chief Executive Officer ,Drug Administration ,Palo Alto ,Ascendi Annual Report ,Pharma Investor Relations ,